Cyclophosphamide, but not CTLA4Ig, prolongs survival of fetal pig islet grafts in anti-T cell monoclonal antibody-treated NOD mice

Xenotransplantation

Volumn 5, Issue 3, 1998, Pages 215-221

  Koulmanda, Maria ^a,b   Kovarik, Jiri ^a   Mandel, Thomas E ^a  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

CTLA4Ig; Cyclophosphamide; Fetal pig islet grafts; Monoclonal antibodies; NOD recipient mice

Indexed keywords

CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; MONOCLONAL ANTIBODY; T LYMPHOCYTE ANTIBODY;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; MOUSE; NONHUMAN; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TREATMENT INDICATION;

EID: 0031694704     PISSN: 0908665X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-3089.1998.tb00030.x     Document Type: Article

References (18)

1. FIRST MR. Transplantation in the nineties. Transplantation 1992:53:1-11.
2. EVANS RW. The actual and potential supply of organ donors in the United States. Clin Transplants 1990:329-341.
3. DIALYNAS DP, QUAN ZS, WALL KA, PIERRES A, QUINTANS J, LOKEN MR, FITCH FW. Characterisation of the murine T cell surface molecule, designated L3T4, identified by monoclonal antibody GK1.5: Similarity of L3T4 to the human Leu-3/T4 molecule. J Immunol 1983:131:2445-2451.
4. MANDEL TE, KOULMANDA M, BACELJ A. Fetal pancreas transplantation in non-obese diabetic (NOD) mice: A comparison of iso-, allo- and xenografts. Horm Res Suppl 1990:25:166-173.
5. MANDEL TE, KOVARIK J, KOULMANDA M. A comparison of organ cultured fetal pancreas allo-, iso-, and xenografts (pig) in non-immunosuppressed non-obese diabetic mice. Am J Pathol 1995:147:834-844.
6. MANDEL TE, KOULMANDA M. The effect of continuous anti-CD4 monoclonal antibody therapy on fetal pig pancreas xenografts in non-obese diabetic mice. Transplant Proc 1990:22:2093-2094.
7. MANDEL TE, KOULMANDA M. Anti-CD3 monoclonal antibody prolongs survival of fetal pig pancreas grafts in NOD mice. Transplant Proc 1992:24:2289-2290.
8. MANDEL TE, KOULMANDA M. Effect of immunosuppression with anti-T-cell monoclonal antibodies on the survival of organ cultured fetal pig xenografts in NOD mice. Transplant Proc 1993:25:2928-2929.
9. MANDEL TE, KOULMANDA M. Anti-T cell monoclonal antibodies for immunosuppression in xenotransplantation of fetal pig pancreas in NOD mice. Transplant Proc 1993:25:796-797.
10. MOORE MJ. Clinical Pharmacokinetics of Cyclophosphamide. Clinical Pharmacokinetics 1991:20:194-208.
11. STARZL TE, FUNG J, TZAKIS A, TODO S, DEMETRIS AJ, MARINO IR ET AL. Baboon-to-human liver transplantation. Lancet 1993:341:65.
12. LENSCHOW DJ, ZENG Y, THISTLETHWAITE JR, MONTAG A, BRADY W, GIBSON MG, LINSLEY PS, BLUESTONE JA. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4IgG. Science 1992:257:789-792.
13. TOMORANI K. A rat antibody against a structure functionally related to the mouse. Immunogenetics 1988: 28:455-458.
14. MANDEL TE, KOULMANDA M. Islet isolation from the fetal pancreas. In: Lanza RP and Chick WL, eds. Pancreatic Islet Transplantation, Vol. 1. Texas: RG Landes Co. 1994, pp. 107-124.
15. SIMEONOVIC CJ, CEREDIG R, WILSON JD. Effect of GK1.5 monoclonal antibody dosage on survival of pig proislet xenografts in CD4+ T cell-depleted mice. Transplantation 1990:49:849-856.
16. MANDEL TE, DILLON H, KOULMANDA M. The effect of a depleting anti-CD4 monoclonal antibody on T cells and fetal pig islet xenograft survival in various strains of mice. Transplant Immunol 1995:3:265-272.
17. CHARLTON B, BACELJ A, SLATTERY RM, MANDEL TE. Cyclophosphamide induced diabetes mellitus in NOD/Wehi mice: Evidence for suppression in spontaneous autoimmune diabetes. Diabetes 1989:38:441-447.
18. WU Y, GUO Y, LIU Y. A major costimulatory molecule on antigen-presenting cells CTLA4 ligand A, is distinct from B7. Journal of experimental Medicine 1993: 178:1789-1793.